Lexaria Bioscience Corp
LEXX
View Detailed Chart
0.725USD
+0.063+9.52%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
16.11MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+9.52%
5 Days
-7.49%
1 Month
+3.44%
6 Months
-13.59%
Year to Date
+17.50%
1 Year
-61.64%
View Detailed Chart
TradingKey Stock Score of Lexaria Bioscience Corp
Currency: USD Updated: 2026-02-06Key Insights
Lexaria Bioscience Corp's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 96 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 4.50.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Lexaria Bioscience Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Lexaria Bioscience Corp Highlights
StrengthsRisks
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. It is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The Company operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 212.07% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 705.92K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 705.92K.
Overvalued
The company’s latest PE is -1.26, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 2.11M shares, decreasing 39.21% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 258.82K shares of this stock.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
4.500
Target Price
+579.76%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Lexaria Bioscience Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Lexaria Bioscience Corp Info
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. It is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The Company operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide.
Ticker SymbolLEXX
CompanyLexaria Bioscience Corp
CEOChristopher (Richard)
Websitehttps://www.lexariabioscience.com/
Related Instruments
+3.66%
+3.17%
+0.93%
+1.99%
+1.78%
+1.60%
-0.95%
+4.49%
+2.10%
+10.00%
+2.72%
+4.15%
+1.81%
+4.17%
+0.72%
+1.06%
+2.46%
0.00%
+0.53%
+0.56%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
69064.510
-905.620 (-1.29%)
282.580
+22.390 (+8.61%)
2067.400
+15.670 (+0.76%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
